Mostrar el registro sencillo del ítem
Clinical Performance of Three Commercial Molecular Diagnostic Assays for the Detection of Fluoroquinolone Resistance-Associated Mutations in Mycoplasma genitalium.
| dc.rights.license | open | en_US |
| dc.contributor.author | GARDETTE, Marie | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | HÉNIN, Nadège | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | LE ROY, Chloé | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | GUIRAUD, Jennifer | |
| dc.contributor.author | TOUATI, Arabella | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | BÉBÉAR, Cécile | |
| hal.structure.identifier | Microbiologie Fondamentale et Pathogénicité [MFP] | |
| dc.contributor.author | PEREYRE, Sabine | |
| dc.date.accessioned | 2024-10-31T08:49:36Z | |
| dc.date.available | 2024-10-31T08:49:36Z | |
| dc.date.issued | 2022-12-21 | |
| dc.identifier.issn | 1098-660X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/203070 | |
| dc.description.abstractEn | The high prevalence of macrolide resistance in Mycoplasma genitalium results in an increased reliance on moxifloxacin, the second-line treatment; however, moxifloxacin resistance has also emerged. Because assays that can detect fluoroquinolone resistance-associated mutations will be useful for the management of macrolide-resistant M. genitalium infections, we evaluated the performance of three commercial assays (the Allplex MG & MoxiR Assay [Seegene], LightMix Modular parC kit [TIBMOLBIOL], and MGMO qPCR [NYtor) in comparison with gene Sanger sequencing used as the reference. Between January 2018 and December 2020, remnants of M. genitalium-positive clinical specimens received at the French National Reference Center for Bacterial Sexually Transmitted Infections were collected if a Sanger sequencing result was obtained for the gene. Overall, 368 M. genitalium-positive specimens were assessed. The clinical sensitivities for the detection of the ParC mutations that are likely of clinical significance were 91.8% (95% CI = 83.2 to 96.2), 98.6% (95% CI = 92.4 to 99.8), and 94.4% (95% CI = 86.6 to 97.8) for the Allplex MG & MoxiR, LightMix Modular parC, and MGMO qPCR kits, respectively, with no significant difference between the three kits. The clinical specificity of the Allplex MG & MoxiR and MGMO qPCR kits was 100% (95% CI = 97.7 to 100 and 98.7 to 100, respectively), which was significantly higher than the specificity of the LightMix Modular parC kit of 95.4% (95%CI = 92.3 to 97.3), for which the interpretation of melting curves may be misleading. These kits should be useful for the selection of antimicrobials in macrolide-resistant M. genitalium infections, although further developments may be necessary because mutations involved in fluoroquinolone resistance have not been precisely determined. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Humans | |
| dc.subject.en | Fluoroquinolones | |
| dc.subject.en | Anti-Bacterial Agents | |
| dc.subject.en | Moxifloxacin | |
| dc.subject.en | Mycoplasma genitalium | |
| dc.subject.en | Pathology | |
| dc.subject.en | Molecular | |
| dc.subject.en | Macrolides | |
| dc.subject.en | Drug Resistance | |
| dc.subject.en | Bacterial | |
| dc.subject.en | Mycoplasma Infections | |
| dc.subject.en | RNA | |
| dc.subject.en | Ribosomal | |
| dc.subject.en | 23S | |
| dc.subject.en | DNA | |
| dc.subject.en | Bacterial | |
| dc.subject.en | Mutation | |
| dc.title.en | Clinical Performance of Three Commercial Molecular Diagnostic Assays for the Detection of Fluoroquinolone Resistance-Associated Mutations in Mycoplasma genitalium. | |
| dc.title.alternative | J Clin Microbiol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1128/jcm.01135-22 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Microbiologie et Parasitologie | en_US |
| dc.identifier.pubmed | 36321820 | en_US |
| bordeaux.journal | Journal of Clinical Microbiology | en_US |
| bordeaux.page | e0113522 | en_US |
| bordeaux.volume | 60 | en_US |
| bordeaux.hal.laboratories | MFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234 | en_US |
| bordeaux.issue | 12 | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | pubmed | |
| hal.identifier | hal-04761397 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-10-31T08:49:39Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| workflow.import.source | pubmed | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Clinical%20Microbiology&rft.date=2022-12-21&rft.volume=60&rft.issue=12&rft.spage=e0113522&rft.epage=e0113522&rft.eissn=1098-660X&rft.issn=1098-660X&rft.au=GARDETTE,%20Marie&H%C3%89NIN,%20Nad%C3%A8ge&LE%20ROY,%20Chlo%C3%A9&GUIRAUD,%20Jennifer&TOUATI,%20Arabella&rft.genre=article |
Archivos en el ítem
| Archivos | Tamaño | Formato | Ver |
|---|---|---|---|
|
No hay archivos asociados a este ítem. |
|||